文献速递泌尿男性生殖肿瘤

恩扎卢胺单药治疗对比主动监测在低危或中危局限性前列腺癌患者中的疗效:ENACT随机临床试验

Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2022-01-01

ENACT是一项2期开放标签随机试验,纳入114例低危或中危局限性前列腺癌患者接受恩扎卢胺160mg单药治疗1年联合主动监测,113例继续主动监测。恩扎卢胺较主动监测显著降低前列腺癌进展风险46%(HR 0.54,95%CI 0.33-0.89,P=0.02),并显著延迟PSA进展6个月(HR 0.71,95%CI 0.53-0.97,P=0.03)。最常见不良事件为疲乏(55.4%)和男性乳房发育(36.6%)。

要点

  • 恩扎卢胺单药治疗1年较主动监测显著降低前列腺癌进展风险(HR 0.54,95%CI 0.33-0.89,P=0.02)。
  • 恩扎卢胺组活检阴性几率是主动监测组的3.5倍,1年时癌阳性穿刺针百分比和PSA二次升高几率显著降低,2年时无显著差异。
  • 恩扎卢胺显著延迟PSA进展6个月(HR 0.71,95%CI 0.53-0.97,P=0.03)。

核心结论

  • 恩扎卢胺单药治疗耐受性良好,在低危或中危局限性前列腺癌患者中显示出显著的治疗反应。
  • 恩扎卢胺可能为接受主动监测的患者提供一种替代治疗选择。

研究设计与样本

  • ENACT研究是一项2期、开放标签、随机临床试验,于2016年6月至2020年8月在美国和加拿大的66个中心开展。
  • 纳入年龄18岁及以上、筛查前6个月内组织学确诊为低危或中危局限性前列腺癌且正在接受主动监测的患者。
  • 患者按1:1随机分配至恩扎卢胺160mg单药治疗1年联合主动监测组或继续主动监测组,按癌症风险和随访活检类型分层。
  • 治疗期间监测1年,随访至2年;数据分析于2021年2月进行。
  • 共114例患者随机分配至恩扎卢胺联合主动监测组,113例分配至主动监测组。

主要发现

  • 恩扎卢胺较主动监测显著降低前列腺癌进展风险46%(HR 0.54,95%CI 0.33-0.89,P=0.02)。
  • 与主动监测相比,恩扎卢胺组活检阴性结果的几率为3.5倍。
  • 恩扎卢胺组1年时癌阳性穿刺针百分比和血清PSA二次升高的几率较主动监测显著降低,2年时无显著差异。
  • 恩扎卢胺较主动监测显著延迟PSA进展6个月(HR 0.71,95%CI 0.53-0.97,P=0.03)。
  • 恩扎卢胺治疗期间最常见的不良事件为疲乏(62例[55.4%])和男性乳房发育(41例[36.6%])。

临床怎么用

  • 作者认为,恩扎卢胺单药治疗可能为接受主动监测的低危或中危局限性前列腺癌患者提供一种替代治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There are few published studies prospectively assessing pharmacological interventions that may delay prostate cancer progression in patients undergoing active surveillance (AS). OBJECTIVE: To compare the efficacy and safety of enzalutamide monotherapy plus AS vs AS alone in patients with low-risk or intermediate-risk prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: The ENACT study was a phase 2, open-label, randomized clinical trial conducted from June 2016 to August 2020 at 66 US and Canadian sites. Eligible patients were 18 years or older, had received a diagnosis of histologically proven low-risk or intermediate-risk localized prostate cancer within 6 months of screening, and were undergoing AS. Patients were monitored during 1 year of treatment and up to 2 years of follow-up. Data analysis was conducted in February 2021. INTERVENTIONS: Randomized 1:1 to enzalutamide, 160 mg, monotherapy for 1 year or continued AS, as stratified by cancer risk and follow-up biopsy type. MAIN OUTCOMES AND MEASURES: The primary end point was time to pathological or therapeutic prostate cancer progression (pathological, ≥1 increase in primary or secondary Gleason pattern or ≥15% increased cancer-positive cores; therapeutic, earliest occurrence of primary therapy for prostate cancer). Secondary end points included incidence of a negative biopsy result, percentage of cancer-positive cores, and incidence of a secondary rise in serum prostate-specific antigen (PSA) levels at 1 and 2 years, as well as time to PSA progression. Adverse events were monitored to assess safety. RESULTS: A total of 114 patients were randomized to treatment with enzalutamide plus AS and 113 to AS alone; baseline characteristics were similar between treatment arms (mean [SD] age, 66.1 [7.8] years; 1 Asian individual [0.4%], 21 Black or African American individuals [9.3%], 1 Hispanic individual [0.4%], and 204 White individuals [89.9%]). Enzalutamide significantly reduced the risk of prostate cancer progression by 46% vs AS (hazard ratio, 0.54; 95% CI, 0.33-0.89; P = .02). Compared with AS, odds of a negative biopsy result were 3.5 times higher; there was a significant reduction in the percentage of cancer-positive cores and the odds of a secondary rise in serum PSA levels at 1 year with treatment with enzalutamide; no significant difference was observed at 2 years. Treatment with enzalutamide also significantly delayed PSA progression by 6 months vs AS (hazard ratio, 0.71; 95% CI, 0.53-0.97; P = .03). The most commonly reported adverse events during enzalutamide treatment were fatigue (62 [55.4%]) and gynecomastia (41 [36.6%]). Three patients in the enzalutamide arm died; none were receiving the study drug at the time of death. No deaths were considered treatment-related. CONCLUSIONS AND RELEVANCE: The results of this randomized clinical trial suggest that enzalutamide monotherapy was well-tolerated and demonstrated a significant treatment response in patients with low-risk or intermediate-risk localized prostate cancer. Enzalutamide may provide an alternative treatment option for patients undergoing AS. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02799745.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Shore ND, Renzulli J, Fleshner NE, et al. Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol. 2022. PMID: 35708696. doi:10.1001/jamaoncol.2022.1641

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。